A Sanofi-backed consortium has won clearance to run a virtual diabetes trial in Europe. The regulatory nod reportedly marks the first time European authorities have green-lit a clinical trial with full electronic informed consent.
President Obama has made the creation of a huge, technically challenging database the centerpiece of his precision medicine proposal. The initiative will draw on existing resources and new studies to gather data on the biology, behavior and health of more than 1 million people. Read more >>
Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, the Biotechnology Industry Organization (BIO) is working to equip small biotechs with the skills they will need if they find themselves in a similar situation. Read more >>
POPULAR COMMENT THREADS
Medidata has struck a deal with Garmin to offer its clients the use of vívofit activity trackers in clinical trials. The choice of vívofit gives an indication of the characteristics clinical trial sponsors may prioritize as wearables start to take off in research.
RainDance Technologies has taken a step toward completing its long-planned IPO by filing the paperwork for a $60 million offering.
Pfizer has updated the risk factors section of its U.S. Securities and Exchange Commission (SEC) filings to reflect the new normal in cybersecurity. The Big Pharma lays out the situation plainly: "As a global pharmaceutical company, our systems are subject to frequent attacks."
LabCorp closed its $5.7 billion takeover of Covance this week and immediately began talking up the potential for its testing data to turbocharge the CRO's clinical trial business.
Eccrine Systems has raised $1.5 million in seed funding to develop a sweat sensor based on know-how that originated at the University of Cincinnati and the Air Force Research Labs. The Cincinnati, Ohio-based startup will use the cash to forge ahead with the development of wearable sensor technology it plans to pitch to clinical trial sponsors.
Novo Nordisk has set the terms for the IPO of its IT services unit NNIT. If NNIT prices at the top end of its range when it goes public in the next week or so, the listing could generate up to $335 million for Novo Nordisk.
From Our Sister Sites
Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.
Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.